Spots Global Cancer Trial Database for carcinoid syndrome
Every month we try and update this database with for carcinoid syndrome cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome | NCT01104415 | Carcinoid Syndr... | Telotristat eti... | 18 Years - | Lexicon Pharmaceuticals | |
| Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms | NCT02026063 | Carcinoid Syndr... | Telotristat eti... | 18 Years - | Lexicon Pharmaceuticals | |
| Telotristat Etiprate for Carcinoid Syndrome Therapy | NCT02063659 | Carcinoid Syndr... | Telotristat eti... Placebo | 18 Years - | Lexicon Pharmaceuticals | |
| Investigation of a Transcatheter Tricuspid Valved Stent Graft in Patients With Carcinoid Heart Disease | NCT05064514 | Tricuspid Regur... Tricuspid Valve... Carcinoid Syndr... Carcinoid Heart... | Transcatheter T... | 18 Years - | Queen Mary University of London | |
| Investigation of a Transcatheter Tricuspid Valved Stent Graft in Patients With Carcinoid Heart Disease | NCT05064514 | Tricuspid Regur... Tricuspid Valve... Carcinoid Syndr... Carcinoid Heart... | Transcatheter T... | 18 Years - | Queen Mary University of London | |
| Study of Panitumumab in the Treatment of Carcinoid Syndrome | NCT01172717 | Carcinoid Syndr... | Panitumumab | 18 Years - | Boston Medical Center | |
| Fibrosis in Chronic and Delayed Myocardial Infarction | NCT05756608 | Aortic Stenosis Chemotherapy In... Carcinoid Syndr... | 68Ga-FAPI and 1... | 40 Years - 90 Years | University of Edinburgh | |
| AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm | NCT03453489 | Carcinoid Syndr... Metastatic Nonf... | Carbon C 11 Alp... Laboratory Biom... Positron Emissi... Telotristat Eti... | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males | NCT01932528 | Carcinoid Syndr... | 500 mg [14C]-LX... | 30 Years - 65 Years | Lexicon Pharmaceuticals | |
| Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome | NCT01018953 | Carcinoid Syndr... | BIM 23A760 | 18 Years - 75 Years | Ipsen | |
| An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors | NCT04993261 | Carcinoid Syndr... Carcinoid Tumor Digestive Syste... Metastatic Carc... | Dual-Energy Com... | 18 Years - | M.D. Anderson Cancer Center | |
| An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome | NCT00774930 | Carcinoid Syndr... | Lanreotide Placebo | 18 Years - | Ipsen | |
| Effects of Serotonin Excess on Bone in Carcinoid Syndrome | NCT01430871 | Carcinoid Syndr... | 18 Years - | Sheffield Teaching Hospitals NHS Foundation Trust | ||
| Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency | NCT04073017 | Neuroendocrine ... Carcinoid Syndr... | Enterade® Functional Asse... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome | NCT04776876 | Advanced Neuroe... Carcinoid Syndr... | Retifanlimab Telotristat Eth... | 18 Years - | M.D. Anderson Cancer Center | |
| Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation | NCT04140409 | Neuroendocrine ... Carcinoid Syndr... | Sandostatin | 18 Years - | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | |
| Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome | NCT04065165 | Small Intestina... Carcinoid Heart... | Telotristat Eth... Lanreotide | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy | NCT04039516 | Carcinoid Heart... Carcinoid Syndr... Carcinoid Tumor | Lutathera | 18 Years - | King's College Hospital NHS Trust | |
| Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO | NCT03223428 | Carcinoid Syndr... | Xermelo | 18 Years - | TerSera Therapeutics LLC | |
| Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) | NCT02299089 | Acromegaly Neuroendocrine ... | octreotide Flui... | 18 Years - | Camurus AB | |
| Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy | NCT00853047 | Carcinoid Syndr... | Telotristat eti... Octreotide LAR ... Placebo | 18 Years - | Lexicon Pharmaceuticals | |
| An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males | NCT01932528 | Carcinoid Syndr... | 500 mg [14C]-LX... | 30 Years - 65 Years | Lexicon Pharmaceuticals | |
| Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome | NCT00884715 | Carcinoid Syndr... | Octreotide | 18 Years - 80 Years | Endo Pharmaceuticals | |
| Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl | NCT04713202 | Neuroendocrine ... Carcinoid Syndr... Diarrhea | Telotristat eth... Peptide Recepto... Placebo | 18 Years - | Big Ten Cancer Research Consortium | |
| AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm | NCT03453489 | Carcinoid Syndr... Metastatic Nonf... | Carbon C 11 Alp... Laboratory Biom... Positron Emissi... Telotristat Eti... | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy | NCT04039516 | Carcinoid Heart... Carcinoid Syndr... Carcinoid Tumor | Lutathera | 18 Years - | King's College Hospital NHS Trust | |
| An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors | NCT04993261 | Carcinoid Syndr... Carcinoid Tumor Digestive Syste... Metastatic Carc... | Dual-Energy Com... | 18 Years - | M.D. Anderson Cancer Center | |
| Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) | NCT02299089 | Acromegaly Neuroendocrine ... | octreotide Flui... | 18 Years - | Camurus AB |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
